The global women health devices market size was estimated to be USD 48.23 billion in 2023 and is expected to reach at USD 133.3 billion by 2033 with a CAGR of 9.68% during the forecast period 2023-2033. Rising awareness regarding women’s health issues, growing prevalence of female cancer such as breast & ovarian cancer, increasing research & development activities, surge in adoption of advanced devices as by younger generation of women as the demographics of women change, growing research & development activities, rising technological advancements, growing mergers & collaborations within market plyers, and increasing launch of cutting-edge diagnostic products are some of the key factors boosting the market growth.
Increasing launch of cutting-edge diagnostic products is predicted to boost the market growth during the forecast period. For instance, In September 2022, Innovative Health Diagnostic has recently introduced the availability of Anti-Mullerian Hormone (AMH) at-home diagnostic tests for online purchase by the general public.
By Product, Contraceptives was the highest revenue-grossing segment in the global women health devices market in 2022 owing to the increasing prevalence of sexually transmitted diseases among women, rising inclination towards planned pregnancy among population, growing demand for contraceptive implants & intrauterine devices, and surge in collaborations within market players for the launch od advance products. For instance, in December 2022, CooperSurgical, Inc. has collaborated with Ostro to introduce a consumer engagement solution for their hormone-free IUD, Paragard. Paragard is an FDA-approved intrauterine device designed to provide up to 10 years of pregnancy prevention. Additionally, Diagnostics is predicted to grow at fastest CAGR during the forecast period owing to the rising prevalence of female cancer & various diseases, growing demand for effective diagnosis devices, and increasing technological advancements.
By Application, Cancers & other chronic diseases was the highest revenue-grossing segment in the global women health devices market in 2022 owing to the growing prevalence of female cancers, rising adoption of effective health devices, increasing demand for medical devices including breast implants, and surge in launch of advanced devices. For instance, in November 2022, Aspira Women’s Health Inc. has recently introduced OvaWatchSM, a novel blood-based test that offers a non-invasive way to assess the risk of ovarian cancer in women who have adnexal masses. Additionally, Pregnancy & Nursing Care is predicted to grow at fastest CAGR during the forecast period owing to the increasing adoption & demand of several critical women’s health devices such as breast pumps & pregnancy diagnostics.
By End-user, Hospitals & clinics was the highest revenue-grossing segment in the global women health devices market in 2022 owing to the surge in number of patients admitting to hospitals for diagnosis & treatment for various diseases linked to women’s health and increasing collaborations within market players. For instance, In October 2022, Aspira Women’s Health Inc. has disclosed a collaborative partnership with BioReference, a prominent full-service specialty laboratory in the U.S. According to the agreement, the companies will jointly market and distribute Ova1Plus, a combination of Aspira’s FDA cleared blood tests, Ova1 and OVERA. This combined test enables the detection of ovarian malignancy risk in women with adnexal masses prior to surgery. Additionally, Home Healthcare is predicted to grow at fastest CAGR during the forecast period owing to the rising utilization of women’s health devices due to ease & convenience and surge in introduction of technologically advanced devices.
North America region is anticipated for the highest revenue share during the forecast period owing to the increasing healthcare expenditure for women’s health, growing demand for technologically advanced devices, and rising initiatives by government & private organizations. For instance, in October 2022, In collaboration with Gender Equality and Youth, the Canadian government has established the National Women's Health Research Initiative (NWHRI) and allocated a financial investment of USD 20.0 million over a span of five years, as outlined in Budget 2021. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the rising improvements in healthcare infrastructure, increasing prevalence of women’s diseases, growing awareness regarding technologically advanced women’s health devices, and surge in product approvals. For instance, in January 2020, Sysmex, a diagnostics company based in Japan, revealed that their in-vitro diagnostic reagent for breast cancer, Lynoamp BC, has obtained Class III approval from China's National Medical Products Administration.
Increasing launch of cutting-edge diagnostic products is predicted to boost the market growth during the forecast period. For instance, In September 2022, Innovative Health Diagnostic has recently introduced the availability of Anti-Mullerian Hormone (AMH) at-home diagnostic tests for online purchase by the general public.
By Product, Contraceptives was the highest revenue-grossing segment in the global women health devices market in 2022 owing to the increasing prevalence of sexually transmitted diseases among women, rising inclination towards planned pregnancy among population, growing demand for contraceptive implants & intrauterine devices, and surge in collaborations within market players for the launch od advance products. For instance, in December 2022, CooperSurgical, Inc. has collaborated with Ostro to introduce a consumer engagement solution for their hormone-free IUD, Paragard. Paragard is an FDA-approved intrauterine device designed to provide up to 10 years of pregnancy prevention. Additionally, Diagnostics is predicted to grow at fastest CAGR during the forecast period owing to the rising prevalence of female cancer & various diseases, growing demand for effective diagnosis devices, and increasing technological advancements.
By Application, Cancers & other chronic diseases was the highest revenue-grossing segment in the global women health devices market in 2022 owing to the growing prevalence of female cancers, rising adoption of effective health devices, increasing demand for medical devices including breast implants, and surge in launch of advanced devices. For instance, in November 2022, Aspira Women’s Health Inc. has recently introduced OvaWatchSM, a novel blood-based test that offers a non-invasive way to assess the risk of ovarian cancer in women who have adnexal masses. Additionally, Pregnancy & Nursing Care is predicted to grow at fastest CAGR during the forecast period owing to the increasing adoption & demand of several critical women’s health devices such as breast pumps & pregnancy diagnostics.
By End-user, Hospitals & clinics was the highest revenue-grossing segment in the global women health devices market in 2022 owing to the surge in number of patients admitting to hospitals for diagnosis & treatment for various diseases linked to women’s health and increasing collaborations within market players. For instance, In October 2022, Aspira Women’s Health Inc. has disclosed a collaborative partnership with BioReference, a prominent full-service specialty laboratory in the U.S. According to the agreement, the companies will jointly market and distribute Ova1Plus, a combination of Aspira’s FDA cleared blood tests, Ova1 and OVERA. This combined test enables the detection of ovarian malignancy risk in women with adnexal masses prior to surgery. Additionally, Home Healthcare is predicted to grow at fastest CAGR during the forecast period owing to the rising utilization of women’s health devices due to ease & convenience and surge in introduction of technologically advanced devices.
North America region is anticipated for the highest revenue share during the forecast period owing to the increasing healthcare expenditure for women’s health, growing demand for technologically advanced devices, and rising initiatives by government & private organizations. For instance, in October 2022, In collaboration with Gender Equality and Youth, the Canadian government has established the National Women's Health Research Initiative (NWHRI) and allocated a financial investment of USD 20.0 million over a span of five years, as outlined in Budget 2021. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the rising improvements in healthcare infrastructure, increasing prevalence of women’s diseases, growing awareness regarding technologically advanced women’s health devices, and surge in product approvals. For instance, in January 2020, Sysmex, a diagnostics company based in Japan, revealed that their in-vitro diagnostic reagent for breast cancer, Lynoamp BC, has obtained Class III approval from China's National Medical Products Administration.
Segmentation: Women Health Devices Market Report 2022 - 2033
Women Health Devices Market Analysis & Forecast by Product 2022 - 2033 (Revenue USD Bn)
- Diagnostics
- Labor & Delivery
- Surgical
- Contraceptives
- Critical Care
- Others
Women Health Devices Market Analysis & Forecast by Application 2022 - 2033 (Revenue USD Bn)
- Reproductive Health
- Cancers & Other Chronic Diseases
- Pregnancy & Nursing Care
- General Health & Wellness
- Pelvic & Uterine Healthcare
- Others
Women Health Devices Market Analysis & Forecast by End-user 2022 - 2033 (Revenue USD Bn)
- Home Healthcare
- Hospitals & Clinics
- Others
Women Health Devices Market Analysis & Forecast by Region 2022 - 2033 (Revenue USD Bn)
North America
- U.S.
- Canada
Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Women Health Devices Market: Product Estimates & Trend Analysis
8. Women Health Devices Market: Application Estimates & Trend Analysis
9. Women Health Devices Market: End-user Estimates & Trend Analysis
10. Regional Market Analysis
11. North America Women Health Devices Market
12. Europe Global Women Health Devices Market
13. Asia Pacific Global Women Health Devices Market
14. Latin America Global Women Health Devices Market
15. MEA Global Women Health Devices Market
16. Competitor Analysis
17. Company Profiles
Companies Mentioned
- Innovative Health Diagnostic
- Coloplast A/S
- Aspira Women’s Health Inc.
- Hologic Inc.
- Sysmex
- Boston Scientific Corporation
- CooperSurgical Inc.
- ALLERGEN (AbbVie Inc.)
- F. Hoffmann-La Roche Ltd
- Becton
- Dickinson and Company
- Reckitt Benckiser Group Plc.
- Caldera Medical
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 145 |
| Published | August 2023 |
| Forecast Period | 2022 - 2033 |
| Estimated Market Value ( USD | $ 48.23 Billion |
| Forecasted Market Value ( USD | $ 133.3 Billion |
| Compound Annual Growth Rate | 9.6% |
| Regions Covered | Global |
| No. of Companies Mentioned | 13 |
